PE20070363A1 - Complejos metalicos con contenido de perfluoroalquilo como medios de contraste en imagenes de resonancia magnetica y procedimientos para su preparacion - Google Patents

Complejos metalicos con contenido de perfluoroalquilo como medios de contraste en imagenes de resonancia magnetica y procedimientos para su preparacion

Info

Publication number
PE20070363A1
PE20070363A1 PE2006000845A PE2006000845A PE20070363A1 PE 20070363 A1 PE20070363 A1 PE 20070363A1 PE 2006000845 A PE2006000845 A PE 2006000845A PE 2006000845 A PE2006000845 A PE 2006000845A PE 20070363 A1 PE20070363 A1 PE 20070363A1
Authority
PE
Peru
Prior art keywords
formula
methyl
magnetic resonance
complex
perfluoroalkyl
Prior art date
Application number
PE2006000845A
Other languages
English (en)
Inventor
Heiko Schirmer
Hanns-Joachim Weinmann
Johannes Platzek
Ludwig Zorn
Bernd Misselwitz
Jorg Meding
Heribert Schmitt-Willich
Thomas Brumby
Original Assignee
Schering Ag
Epix Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102005033903A external-priority patent/DE102005033903B4/de
Application filed by Schering Ag, Epix Pharm Inc filed Critical Schering Ag
Publication of PE20070363A1 publication Critical patent/PE20070363A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R ES UN MONO U OLIGOSACARIDO OPCIONALMENTE PERALQUILADO, COMPLEJOS K DE FORMULA (II), (IV), ENTRE OTROS; Q ES UN ENLACE DIRECTO, ?-(CH2)m-?, ENTRE OTROS, DONDE ? Y ? SON SITIOS DE UNION; Rf ES UNA CADENA DE CARBONOS PERFLUORADA DE FORMULA CnF2nE, DONDE E ES F, Cl, Br, I O H; n ES DE 4 A 30; X ES UN COMPUESTO DE FORMULA (XI) DONDE G ES -O- O -SO2-; s Y s' SON 1 O 2; t ES 0 O 1; ? Y ? SON SITIOS DE UNION; K ES UN COMPLEJO METALICO DE FORMULA (II), (IV), ENTRE OTROS, DONDE R1 ES H O UN EQUIVALENTE DE IONES METALICOS DE NUMEROS ATOMICOS 21-29, 31-33, ENTRE OTROS; R2 Y R3 SON ALQUILO(C1-C7), BENCILO, ENTRE OTROS; U ES FENILENO, ALQUILENO(C1-C12), ENTRE OTROS; L ES UN COMPUESTO DE FORMULA (IXa), (IXc), ENTRE OTROS, DONDE ?, ? Y ? SON SITIOS DE UNION; A ES UNA CADENA DE CARBONOS (C1-C15). SON COMPUESTOS PREFERIDOS: COMPLEJO DE GADOLINIO DE 6-N-[1,4,7-TRIS-(CARBOXILATOMETIL)-1,4,7,10-TETRAAZACICLODODECAN-10-N-(PENTANOIL-3-AZA-4-OXO-5-METIL-5-IL)]-2-N-(1-O-?-d-CARBONILMETILMANOPIRANOSA)-L-LISIN-[(1H,1H,2H,2H-PERFLUORODECIL)-METIL]-AMIDA, COMPLEJO DE GADOLINIO DE 6-N-[1,4,7-TRIS-(CARBOXILATOMETIL)-1,4,7,10-TETRAAZACICLODODECAN-10-N-(PENTANOIL-3-AZA-4-OXO-5-METIL-5-IL)]-2-N-(1-O-?-d-CARBONILMETILMANOPIRANOSA)-L-LISIN-[(1H,1H,2H,2H-PERFLUOROOCTIL)-METIL]-AMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON UTILES PARA EL DIAGNOSTICO POR RESONANCIA MAGNETICA, RAYOS X
PE2006000845A 2005-07-15 2006-07-14 Complejos metalicos con contenido de perfluoroalquilo como medios de contraste en imagenes de resonancia magnetica y procedimientos para su preparacion PE20070363A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005033903A DE102005033903B4 (de) 2005-07-15 2005-07-15 Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel
EP05090230 2005-08-10

Publications (1)

Publication Number Publication Date
PE20070363A1 true PE20070363A1 (es) 2007-04-20

Family

ID=38813200

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000845A PE20070363A1 (es) 2005-07-15 2006-07-14 Complejos metalicos con contenido de perfluoroalquilo como medios de contraste en imagenes de resonancia magnetica y procedimientos para su preparacion

Country Status (10)

Country Link
US (1) US20070020183A1 (es)
EP (1) EP1904462A2 (es)
JP (1) JP2009509915A (es)
CA (1) CA2615434A1 (es)
DO (1) DOP2006000166A (es)
GT (1) GT200600314A (es)
PE (1) PE20070363A1 (es)
TW (1) TW200740777A (es)
UY (1) UY29663A1 (es)
WO (1) WO2007009637A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618957B2 (en) * 2005-07-15 2009-11-17 Bayer Schering Pharma Aktiengesellschaft Perfluoroalkyl-containing complexes, process for their production as well as their use
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
US7810965B2 (en) 2008-03-02 2010-10-12 Lumenetix, Inc. Heat removal system and method for light emitting diode lighting apparatus
US7969075B2 (en) 2009-02-10 2011-06-28 Lumenetix, Inc. Thermal storage system using encapsulated phase change materials in LED lamps
US8760265B2 (en) * 2009-05-08 2014-06-24 Apple Inc. Remote control signal learning and processing by a host device and accessory
US9593170B2 (en) * 2013-05-09 2017-03-14 Canon Kabushiki Kaisha Compound, photocurable composition, and methods for producing patterned film, optical component, circuit board, electronic component by using the photocurable composition, and cured product
JP7191938B2 (ja) 2017-05-05 2022-12-19 センター・フォー・プローブ・デベロップメント・アンド・コマーシャライゼイション Ｉｇｆ－１ｒモノクローナル抗体及びその使用
CA3062553C (en) 2017-05-05 2024-02-06 Fusion Pharmaceuticals Inc. Pharmacokinetic enhancements of bifunctional chelates and uses thereof
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
CN114181164A (zh) * 2021-12-13 2022-03-15 武汉大学中南医院 基于Fe(Ⅱ)特异性MRI对比剂的合成方法及其应用
CN114085619B (zh) * 2021-12-23 2022-07-15 泰州亚德胶粘制品有限公司 一种耐高温低粘着光学胶粘剂及其制备方法
CN115308319A (zh) * 2022-06-28 2022-11-08 北京大学 一种全氟及多氟烷基化合物非靶向筛查的定量方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10040381C1 (de) * 2000-08-11 2002-06-06 Schering Ag Perfluoralkylhaltige Komplexe mit Zuckerresten, Verfahren zu deren Herstellung und ihre Verwendung
US6676928B2 (en) * 2000-08-11 2004-01-13 Schering Aktiengesellschaft Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use
US6818203B2 (en) * 2000-08-11 2004-11-16 Schering Aktiengesellschaft Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses
DE10040858C2 (de) * 2000-08-11 2003-12-18 Schering Ag Perfluoralkylhaltige Komplexe mit polaren Resten, Verfahren zu deren Herstellung und ihre Verwendung
US6641797B2 (en) * 2000-08-11 2003-11-04 Schering Aktiengesellschaft Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use
US7334704B1 (en) * 2005-01-25 2008-02-26 William C Bynum Apparatus for flattening the walls of flexible tubes
US7618957B2 (en) * 2005-07-15 2009-11-17 Bayer Schering Pharma Aktiengesellschaft Perfluoroalkyl-containing complexes, process for their production as well as their use

Also Published As

Publication number Publication date
JP2009509915A (ja) 2009-03-12
TW200740777A (en) 2007-11-01
GT200600314A (es) 2007-07-05
CA2615434A1 (en) 2007-01-25
WO2007009637A3 (de) 2007-05-10
WO2007009637A2 (de) 2007-01-25
DOP2006000166A (es) 2007-02-28
UY29663A1 (es) 2007-02-28
EP1904462A2 (de) 2008-04-02
US20070020183A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
PE20070363A1 (es) Complejos metalicos con contenido de perfluoroalquilo como medios de contraste en imagenes de resonancia magnetica y procedimientos para su preparacion
NO20064011L (no) Kontrastmidler for myokardial perfusjonsbilleddannelse
RU2448106C2 (ru) Новые гетероарил-замещенные бензотиазолы
SG152254A1 (en) Contrast agents for myocardial perfusion imaging
EA200701799A1 (ru) Транс-каротиноиды, синтез указанных каротиноидов, получение композиций и их применение
RU2008119842A (ru) Производные триазола в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы-1
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
EA200800848A1 (ru) Тиазолы в качестве фунгицидных средств
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
CL2012000284A1 (es) Compuestos derivados de pirimidinio; y composicion que comprende dicho compuesto y al menos un agente biologicamente activo.
MX2010009959A (es) Compuestos y metodo para reducir el acido urico.
PA8546301A1 (es) Resolucion de sal quiral
AR073922A1 (es) 2- oxoquinoxalinas como bloqueadores de los canales de sodio tardios
PE20081837A1 (es) Derivados de quinuclinidol como antagonistas de los receptores muscarinicos
RU2011108837A (ru) Новый способ и применение несимметрично мезозамещенных порфиринов и хлоринов для фдт
TN2009000063A1 (en) Compounds and methods for 18f labeled agents
RU2008130043A (ru) Комбинация, включающая комбретастатин и противораковые средства
EA201070250A1 (ru) Противомикробный парентеральный состав
MX341173B (es) Proceso de fluorinado de derivados de anilida y derivados de fluorinado de benzotiazole en la forma de agentes de generacion de imagen in vivo.
PE20061446A1 (es) Compuestos de bencimidazol-carboxamida como agonistas de receptores 5-ht4
AR074593A1 (es) Benzotiazol amidas para la deteccion del peptido beta amiloide
PE20061063A1 (es) Derivados de taxanos como agentes citotoxicos
HRP20050158A2 (en) Novel 2-arylthiazole compounds as pparalpha and ppargama agonists
MA33917B1 (fr) Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitue

Legal Events

Date Code Title Description
FD Application declared void or lapsed